Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Iovance Therapeutics: Historic Product, Tough Commercial Outlook [Seeking Alpha]

Lyell Immunopharma, Inc. (LYEL) 
Company Research Source: Seeking Alpha
Follow Summary Iovance's cell therapy Amtagvi has received an historic FDA approval for treating unresectable or metastatic melanoma, but its stock has fallen over 70% since 2020. Despite first revenues from Amtagvi and Proleukin in Q2, financial uncertainties and a high cash burn raise concerns about Iovance's long-term profitability and market viability. Management's lack of detailed revenue breakdown and challenges with insurance approvals and competition create a little uncertainty around Amtagvi's commercial success. While promising label expansions and full approval could boost prospects, current financial, regulatory, and commercial uncertainties justify maintaining a "Hold" rating. CIPhotos/iStock via Getty Images Investment Overview - Iovance's Historic Approval Dovetails With Its Historic Share Price Losses I first initiated coverage on Iovance Therapeutics ( NASDAQ: IOVA ) for Seeking Alpha back in April 2020, giving the company's stock a "Buy" recommendati Show less Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
LYEL alerts

from News Quantified
Opt-in for
LYEL alerts

from News Quantified